Mislen Bauer
Miami, FLNPI 1447295217
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,725 of the $28,593 with a category attached, or 62.0%. Biomarin Pharmaceutical Inc. accounts for 65.7% of it on its own, with 15 other manufacturers making up the rest.
Across 96 payments — averaging $297.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$19K
- AstraZeneca$9K
- NS Pharma, Inc.$294
- Sanofi$202
- Takeda Pharmaceuticals U.S.A., Inc.$80
- Springworks Therapeutics, Inc.$76
- plus $297 from 10 others
Across 15 payments — averaging $2625.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$39K
What the payments were for
- Consulting fees$1,5946%
- Speaking & faculty fees$17,72562%
- Travel & lodging$6,48523%
- Food & beverage$2,7159%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 34 | $18,796 |
| AstraZeneca(2 entities) | 27 | $8,849 |
| NS Pharma, Inc. | 11 | $294 |
| Sanofi | 5 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| Springworks Therapeutics, Inc. | 3 | $76 |
| Ipsen Biopharmaceuticals, Inc | 2 | $57 |
| Kyowa Kirin, Inc. | 2 | $52 |
| PTC Therapeutics, Inc. | 1 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Pharming Healthcare, Inc. | 1 | $28 |
| Mirum Pharmaceuticals, Inc. | 1 | $25 |
| Mauna Kea Technologies, Inc. | 1 | $24 |
| Biogen | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOXZOGO 1.2mg$11,416
- KOSELUGO$6,730
- Vimizim$2,500
- Strensiq$132
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VimizimElosulfase Alfa | 11 | $705,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Vimizim | $18,796 | $705,39611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Floridaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.